In our study, significant associations were identified between PSMA (p ≤ 0.001) and PCA3 (p ≤ 0.05) expression and clinically significant prostate cancer (Figure 1 and Figure S1a), and among the three genes examined, PSMA emerged as the most reliable single biomarker for predicting clinically significant PCa with an AUC of 0.82 (Figure 2). The gene discussed is FOLH1; the disease is prostate cancer.